{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:03:33Z","timestamp":1790391813219,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jdcr.2026.08.030","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:45:20Z","timestamp":1787931920000},"page":"4-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Type 1 segmental Darier disease unmasked by enfortumab vedotin"],"prefix":"10.1016","volume":"77","author":[{"given":"Nina B.","family":"Curkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheba Jaison","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Vandergriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Heberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2026.08.030_bib1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/jdv.20448","article-title":"Darier disease: current insights and challenges in pathogenesis and management","volume":"39","author":"Ettinger","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jdcr.2026.08.030_bib2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1346-8138.2007.00379.x","article-title":"Localized Darier's disease in a Blaschkoid distribution: two cases of phenotypic mosaicism and a review of mosaic Darier's disease","volume":"34","author":"Sanderson","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdcr.2026.08.030_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with Enfortumab vedotin: a real-word Study leveraging U.S. food and drug administration adverse event reporting System","volume":"11","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.jdcr.2026.08.030_bib4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/DAD.0000000000002255","article-title":"Enfortumab Vedotin\u2013Associated toxic epidermal necrolysis-like toxic erythema of chemotherapy","volume":"44","author":"Birmingham","year":"2022","journal-title":"The Am J Dermatopathology"},{"key":"10.1016\/j.jdcr.2026.08.030_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdin.2022.10.004","article-title":"Characterization of cutaneous adverse events to enfortumab vedotin: a retrospective case-control study","volume":"10","author":"Shahin","year":"2022","journal-title":"JAAD Int"},{"issue":"3","key":"10.1016\/j.jdcr.2026.08.030_bib6","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jdcr.2026.08.030_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdcr.2024.12.019","article-title":"Clinical and histopathological characterization of enfortumab vedotin-associated cutaneous toxicities: a case series","volume":"57","author":"Egbeto","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.030_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cup.14327","article-title":"The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy","volume":"50","author":"Seervai","year":"2023","journal-title":"J Cutan Pathol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:49Z","timestamp":1790391229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626005242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":8,"alternative-id":["S2352512626005242"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.030","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 1 segmental Darier disease unmasked by enfortumab vedotin","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}